Differences between generic and branded eye drops - Dr. Andrew Meagher
In this episode, we review differences in regulatory requirements for branded and generic therapeutic agents, and how these differences can manifest in eye care. Dr. Andrew Meagher sheds light on the subject using IOP-lowering glaucoma drops as an example.
Drawing on his experience in the clinic and keen attention to scientific detail, Dr. Meagher shares knowledge as Associate Professor at the Salus University, School of Optometry.
For more information on the guest, check out our website: http://broadeye.org/meagher/
Listen on Spotify: https://spoti.fi/31XqFak
Listen on Google Podcasts: https://bit.ly/30qrtUr
Listen on Apple Podcasts: https://apple.co/3ouneQh
Follow us on Social Media:
Facebook: / broadeyepodcast
LinkedIn: / broa. .
Twitter: / broadeyepodcast
00:00 Intro
01:29 How did you first get interested in the topic?
06:22 Differences in regulations
10:58 Has there been an increase of the market share of generics?
12:21 What could be changed to make generics available but make sure they work properly?
17:06 Do the same ingredients equal the same effect?
19:02 Did the pandemic make it harder to monitor what patients are on?
21:52 Conclusion